Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrolapitant + palonosetron with or without dexamethasone for CINV in NSCLC patients on ICI + chemotherapy
ChiCTR2600124790Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fosrolapitant, palonosetron and dexamethasone in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Complete response rate during overall period of first chemotherapy cycle. Planned start May 2026; status: not yet recruiting.
02
Drugs
fosrolapitantpalonosetrondexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2600124790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124790.